Gritstone bio - GRTS Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GRTS shares.
View GRTS analyst ratings or view top-rated stocks.

1 brokerages have issued 1-year target prices for Gritstone bio's shares. Their GRTS share price forecasts range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next year. This suggests a possible upside of 244.8% from the stock's current price.
View analysts price targets for GRTS or view top-rated stocks among Wall Street analysts.

Gritstone bio's stock was trading at $12.86 at the start of the year. Since then, GRTS stock has decreased by 72.9% and is now trading at $3.48.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our GRTS earnings forecast.

Gritstone bio, Inc. (NASDAQ:GRTS) issued its earnings results on Thursday, August, 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.06. Gritstone bio had a negative trailing twelve-month return on equity of 59.91% and a negative net margin of 634.23%. During the same quarter in the previous year, the business earned ($0.33) EPS.

1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL).

(GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.

Gritstone bio trades on the NASDAQ under the ticker symbol "GRTS."

Gritstone bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (1.36%), SkyOak Wealth LLC (0.18%), Russell Investments Group Ltd. (0.09%), Connor Clark & Lunn Investment Management Ltd. (0.02%), Institute for Wealth Management LLC. (0.02%) and Key Client Fiduciary Advisors LLC (0.01%). Insiders that own company stock include Erin Jones and Raphael Rousseau.
View institutional ownership trends.

Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GRTS stock can currently be purchased for approximately $3.48.

Gritstone bio (NASDAQ:GRTS) has a market capitalization of $253.39 million and generates $48.21 million in revenue each year. The company earns $-75,080,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

The company employs 193 workers across the globe.

Gritstone bio's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The official website for the company is www.gritstoneoncology.com. The company can be reached via phone at (510) 871-6100 or via email at ir@gritstone.com.